Top

Molecular Pain

Published in:

Open Access 01-12-2013 | Research

Transcriptional mechanisms underlying sensitization of peripheral sensory neurons by Granulocyte-/Granulocyte-macrophage colony stimulating factors

Authors: Kiran Kumar Bali, Varun Venkataramani, Venkata P Satagopam, Pooja Gupta, Reinhard Schneider, Rohini Kuner

Published in: Molecular Pain | Issue 1/2013

Abstract

Background

Cancer-associated pain is a major cause of poor quality of life in cancer patients and is frequently resistant to conventional therapy. Recent studies indicate that some hematopoietic growth factors, namely granulocyte macrophage colony stimulating factor (GMCSF) and granulocyte colony stimulating factor (GCSF), are abundantly released in the tumor microenvironment and play a key role in regulating tumor-nerve interactions and tumor-associated pain by activating receptors on dorsal root ganglion (DRG) neurons. Moreover, these hematopoietic factors have been highly implicated in postsurgical pain, inflammatory pain and osteoarthritic pain. However, the molecular mechanisms via which G-/GMCSF bring about nociceptive sensitization and elicit pain are not known.

Results

In order to elucidate G-/GMCSF mediated transcriptional changes in the sensory neurons, we performed a comprehensive, genome-wide analysis of changes in the transcriptome of DRG neurons brought about by exposure to GMCSF or GCSF. We present complete information on regulated genes and validated profiling analyses and report novel regulatory networks and interaction maps revealed by detailed bioinformatics analyses. Amongst these, we validate calpain 2, matrix metalloproteinase 9 (MMP9) and a RhoGTPase Rac1 as well as Tumor necrosis factor alpha (TNFα) as transcriptional targets of G-/GMCSF and demonstrate the importance of MMP9 and Rac1 in GMCSF-induced nociceptor sensitization.

Conclusion

With integrative approach of bioinformatics, in vivo pharmacology and behavioral analyses, our results not only indicate that transcriptional control by G-/GMCSF signaling regulates a variety of established pain modulators, but also uncover a large number of novel targets, paving the way for translational analyses in the context of pain disorders.

Available only for authorised users

Jimenez-Andrade JM, Mantyh WG, Bloom AP, Ferng AS, Geffre CP, Mantyh PW: Bone cancer pain. Ann N Y Acad Sci 2010, 1198: 173–181. 10.1111/j.1749-6632.2009.05429.xCrossRefPubMed

Davar G: Endothelin-1 and metastatic cancer pain. Pain Med 2001, 2: 24–27. 10.1046/j.1526-4637.2001.002001024.xCrossRefPubMed

Grant K, Loizidou M, Taylor I: Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 2003, 88: 163–166. 10.1038/sj.bjc.6700750PubMedCentralCrossRefPubMed

Stosser S, Agarwal N, Tappe-Theodor A, Yanagisawa M, Kuner R: Dissecting the functional significance of endothelin A receptors in peripheral nociceptors in vivo via conditional gene deletion. Pain 2009, 148: 206–214.CrossRefPubMed

Mantyh PW: Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 2006, 7: 797–809.CrossRefPubMed

Stosser S, Schweizerhof M, Kuner R: Hematopoietic colony-stimulating factors: new players in tumor-nerve interactions. J Mol Med (Berl) 2011, 89: 321–329. 10.1007/s00109-010-0697-zCrossRef

Hamilton JA: Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008, 8: 533–544. 10.1038/nri2356CrossRefPubMed

Schweizerhof M, Stosser S, Kurejova M, Njoo C, Gangadharan V, Agarwal N, Schmelz M, Bali KK, Michalski CW, Brugger S, et al.: Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med 2009, 15: 802–807. 10.1038/nm.1976CrossRefPubMed

Cook AD, Pobjoy J, Sarros S, Steidl S, Durr M, Lacey DC, Hamilton JA: Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain. Ann Rheum Dis 2013, 72: 265–270. 10.1136/annrheumdis-2012-201703CrossRefPubMed

10.

Cook AD, Pobjoy J, Steidl S, Durr M, Braine EL, Turner AL, Lacey DC, Hamilton JA: Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res Ther 2012, 14: R199. 10.1186/ar4037PubMedCentralCrossRefPubMed

11.

Leah E: Experimental arthritis: GM-CSF mediates pain and disease in a mouse model of osteoarthritis. Nat Rev Rheumatol 2012, 8: 634.CrossRefPubMed

12.

Onuora S: Pain: granulocyte-macrophage colony-stimulating factor required for inflammatory and arthritic pain. Nat Rev Rheumatol 2012, 8: 499. 10.1038/nrrheum.2012.139CrossRefPubMed

13.

Rawlings JS, Rosler KM, Harrison DA: The JAK/STAT signaling pathway. J Cell Sci 2004, 117: 1281–1283. 10.1242/jcs.00963CrossRefPubMed

14.

Boyd TD, Bennett SP, Mori T, Governatori N, Runfeldt M, Norden M, Padmanabhan J, Neame P, Wefes I, Sanchez-Ramos J, et al.: GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. J Alzheimers Dis 2010, 21: 507–518.PubMed

15.

Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP: G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009, 5: 554–559. 10.1038/nrrheum.2009.178CrossRefPubMed

16.

Chudin E, Kruglyak S, Baker SC, Oeser S, Barker D, McDaniel TK: A model of technical variation of microarray signals. J Comput Biol 2006, 13: 996–1003. 10.1089/cmb.2006.13.996CrossRefPubMed

17.

Fu WJ, Hu J, Spencer T, Carroll R, Wu G: Statistical models in assessing fold change of gene expression in real-time RT-PCR experiments. Comput Biol Chem 2006, 30: 21–26. 10.1016/j.compbiolchem.2005.10.005CrossRefPubMed

18.

Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19: 185–193. 10.1093/bioinformatics/19.2.185CrossRefPubMed

19.

Simonetti M, Hagenston AM, Vardeh D, Freitag HE, Mauceri D, Lu J, Satagopam VP, Schneider R, Costigan M, Bading H, Kuner R: Nuclear calcium signaling in spinal neurons drives a genomic program required for persistent inflammatory pain. Neuron 2013, 77: 43–57. 10.1016/j.neuron.2012.10.037PubMedCentralCrossRefPubMed

20.

Quick ML, Mukherjee S, Rudick CN, Done JD, Schaeffer AJ, Thumbikat P: CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis. Am J Physiol Regul Integr Comp Physiol 2012, 303: R580-R589. 10.1152/ajpregu.00240.2012PubMedCentralCrossRefPubMed

21.

Zhang N, Rogers TJ, Caterina M, Oppenheim JJ: Proinflammatory chemokines, such as C-C chemokine ligand 3, desensitize mu-opioid receptors on dorsal root ganglia neurons. J Immunol 2004, 173: 594–599.CrossRefPubMed

22.

Julius D, Basbaum AI: Molecular mechanisms of nociception. Nature 2001, 413: 203–210. 10.1038/35093019CrossRefPubMed

23.

Tulleuda A, Cokic B, Callejo G, Saiani B, Serra J, Gasull X: TRESK channel contribution to nociceptive sensory neurons excitability: modulation by nerve injury. Mol Pain 2011, 7: 30. 10.1186/1744-8069-7-30PubMedCentralCrossRefPubMed

24.

Dong H, O’Brien RJ, Fung ET, Lanahan AA, Worley PF, Huganir RL: GRIP: a synaptic PDZ domain-containing protein that interacts with AMPA receptors. Nature 1997, 386: 279–284. 10.1038/386279a0CrossRefPubMed

25.

Tao YX: Dorsal horn alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor trafficking in inflammatory pain. Anesthesiology 2010, 112: 1259–1265. 10.1097/ALN.0b013e3181d3e1edPubMedCentralCrossRefPubMed

26.

Liou JT, Yuan HB, Mao CC, Lai YS, Day YJ: Absence of C-C motif chemokine ligand 5 in mice leads to decreased local macrophage recruitment and behavioral hypersensitivity in a murine neuropathic pain model. Pain 2012, 153: 1283–1291. 10.1016/j.pain.2012.03.008CrossRefPubMed

27.

Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK: Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 2002, 41: 484–489. 10.1093/rheumatology/41.5.484CrossRef

28.

Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, Emery P: Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003, 42: 83–88. 10.1093/rheumatology/keg037CrossRef

29.

Ekins S, Nikolsky Y, Bugrim A, Kirillov E, Nikolskaya T: Pathway mapping tools for analysis of high content data. Methods Mol Biol 2007, 356: 319–350.PubMed

30.

Lee KM, Kang BS, Lee HL, Son SJ, Hwang SH, Kim DS, Park JS, Cho HJ: Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity. Eur J Neurosci 2004, 19: 3375–3381. 10.1111/j.0953-816X.2004.03441.xCrossRefPubMed

31.

Tan AM, Stamboulian S, Chang YW, Zhao P, Hains AB, Waxman SG, Hains BC: Neuropathic pain memory is maintained by Rac1-regulated dendritic spine remodeling after spinal cord injury. J Neurosci 2008, 28: 13173–13183. 10.1523/JNEUROSCI.3142-08.2008CrossRefPubMed

32.

Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y: Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA 2004, 101: 7618–7623. 10.1073/pnas.0307512101PubMedCentralCrossRefPubMed

33.

Chattopadhyay S, Myers RR, Janes J, Shubayev V: Cytokine regulation of MMP-9 in peripheral glia: implications for pathological processes and pain in injured nerve. Brain Behav Immun 2007, 21: 561–568. 10.1016/j.bbi.2006.10.015PubMedCentralCrossRefPubMed

34.

Ji RR, Xu ZZ, Wang X, Lo EH: Matrix metalloprotease regulation of neuropathic pain. Trends Pharmacol Sci 2009, 30: 336–340. 10.1016/j.tips.2009.04.002PubMedCentralCrossRefPubMed

35.

Kawasaki Y, Xu ZZ, Wang X, Park JY, Zhuang ZY, Tan PH, Gao YJ, Roy K, Corfas G, Lo EH, Ji RR: Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008, 14: 331–336. 10.1038/nm1723PubMedCentralCrossRefPubMed

36.

Kular L, Rivat C, Lelongt B, Calmel C, Laurent M, Pohl M, Kitabgi P, Melik-Parsadaniantz S, Martinerie C: NOV/CCN3 attenuates inflammatory pain through regulation of matrix metalloproteinases-2 and −9. J Neuroinflammation 2012, 9: 36. 10.1186/1742-2094-9-36PubMedCentralCrossRefPubMed

37.

Kunz S, Niederberger E, Ehnert C, Coste O, Pfenninger A, Kruip J, Wendrich TM, Schmidtko A, Tegeder I, Geisslinger G: The calpain inhibitor MDL 28170 prevents inflammation-induced neurofilament light chain breakdown in the spinal cord and reduces thermal hyperalgesia. Pain 2004, 110: 409–418. 10.1016/j.pain.2004.04.031CrossRefPubMed

38.

Xie W, Uchida H, Nagai J, Ueda M, Chun J, Ueda H: Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain. J Neurochem 2010, 113: 1002–1011. 10.1111/j.1471-4159.2010.06664.xPubMedCentralCrossRefPubMed

39.

Abram SE, Yi J, Fuchs A, Hogan QH: Permeability of injured and intact peripheral nerves and dorsal root ganglia. Anesthesiology 2006, 105: 146–153. 10.1097/00000542-200607000-00024CrossRefPubMed

40.

Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O: Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol 2011, 48: 135–142. 10.1007/s00592-010-0237-xCrossRefPubMed

41.

Shubayev VI, Myers RR: Anterograde TNF alpha transport from rat dorsal root ganglion to spinal cord and injured sciatic nerve. Neurosci Lett 2002, 320: 99–101. 10.1016/S0304-3940(02)00010-1CrossRefPubMed

42.

Constantin CE, Mair N, Sailer CA, Andratsch M, Xu ZZ, Blumer MJ, Scherbakov N, Davis JB, Bluethmann H, Ji RR, Kress M: Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J Neurosci 2008, 28: 5072–5081. 10.1523/JNEUROSCI.4476-07.2008CrossRefPubMed

43.

Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR: Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121: 1088–1094. 10.1053/gast.2001.28674CrossRefPubMed

44.

Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000, 342: 763–769. 10.1056/NEJM200003163421103CrossRefPubMed

45.

Cuellar JM, Montesano PX, Carstens E: Role of TNF-alpha in sensitization of nociceptive dorsal horn neurons induced by application of nucleus pulposus to L5 dorsal root ganglion in rats. Pain 2004, 110: 578–587. 10.1016/j.pain.2004.03.029CrossRefPubMed

46.

Czeschik JC, Hagenacker T, Schafers M, Busselberg D: TNF-alpha differentially modulates ion channels of nociceptive neurons. Neurosci Lett 2008, 434: 293–298. 10.1016/j.neulet.2008.01.070CrossRefPubMed

47.

Erschbamer MK, Hofstetter CP, Olson L: RhoA, RhoB, RhoC, Rac1, Cdc42, and Tc10 mRNA levels in spinal cord, sensory ganglia, and corticospinal tract neurons and long-lasting specific changes following spinal cord injury. J Comp Neurol 2005, 484: 224–233. 10.1002/cne.20471CrossRefPubMed

48.

Nakayama AY, Harms MB, Luo L: Small GTPases Rac and Rho in the maintenance of dendritic spines and branches in hippocampal pyramidal neurons. J Neurosci 2000, 20: 5329–5338.PubMed

49.

Tashiro A, Minden A, Yuste R: Regulation of dendritic spine morphology by the rho family of small GTPases: antagonistic roles of Rac and Rho. Cereb Cortex 2000, 10: 927–938. 10.1093/cercor/10.10.927CrossRefPubMed

50.

Tashiro A, Yuste R: Regulation of dendritic spine motility and stability by Rac1 and Rho kinase: evidence for two forms of spine motility. Mol Cell Neurosci 2004, 26: 429–440. 10.1016/j.mcn.2004.04.001CrossRefPubMed

51.

Woessner JF Jr: The family of matrix metalloproteinases. Ann N Y Acad Sci 1994, 732: 11–21. 10.1111/j.1749-6632.1994.tb24720.xCrossRefPubMed

52.

Rosenberg GA: Matrix metalloproteinases in neuroinflammation. Glia 2002, 39: 279–291. 10.1002/glia.10108CrossRefPubMed

53.

Parks WC, Wilson CL, Lopez-Boado YS: Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004, 4: 617–629. 10.1038/nri1418CrossRefPubMed

54.

Yong VW: Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005, 6: 931–944. 10.1038/nrn1807CrossRefPubMed

55.

Demestre M, Wells GM, Miller KM, Smith KJ, Hughes RA, Gearing AJ, Gregson NA: Characterisation of matrix metalloproteinases and the effects of a broad-spectrum inhibitor (BB-1101) in peripheral nerve regeneration. Neuroscience 2004, 124: 767–779. 10.1016/j.neuroscience.2003.12.037CrossRefPubMed

56.

Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S, Miller KM, Hauser SL, Kappos L: Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998, 121(Pt 12):2327–2334.CrossRefPubMed

57.

Li G, Iyengar R: Calpain as an effector of the Gq signaling pathway for inhibition of Wnt/beta -catenin-regulated cell proliferation. Proc Natl Acad Sci USA 2002, 99: 13254–13259. 10.1073/pnas.202355799PubMedCentralCrossRefPubMed

58.

Neumar RW, Xu YA, Gada H, Guttmann RP, Siman R: Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. J Biol Chem 2003, 278: 14162–14167. 10.1074/jbc.M212255200CrossRefPubMed

59.

Saito Y, Saido TC, Sano K, Kawashima S: The calpain-calpastatin system is regulated differently during human neuroblastoma cell differentiation to Schwannian and neuronal cells. FEBS Lett 1994, 353: 327–331. 10.1016/0014-5793(94)01075-7CrossRefPubMed

60.

Vanderklish PW, Krushel LA, Holst BH, Gally JA, Crossin KL, Edelman GM: Marking synaptic activity in dendritic spines with a calpain substrate exhibiting fluorescence resonance energy transfer. Proc Natl Acad Sci USA 2000, 97: 2253–2258. 10.1073/pnas.040565597PubMedCentralCrossRefPubMed

61.

Chera B, Schaecher KE, Rocchini A, Imam SZ, Ray SK, Ali SF, Banik NL: Calpain upregulation and neuron death in spinal cord of MPTP-induced parkinsonism in mice. Ann N Y Acad Sci 2002, 965: 274–280.CrossRefPubMed

62.

Baliova M, Betz H, Jursky F: Calpain-mediated proteolytic cleavage of the neuronal glycine transporter, GlyT2. J Neurochem 2004, 88: 227–232.CrossRefPubMed

63.

Chan SL, Mattson MP: Caspase and calpain substrates: roles in synaptic plasticity and cell death. J Neurosci Res 1999, 58: 167–190. 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-KCrossRefPubMed

64.

Banik NL, Matzelle D, Gantt-Wilford G, Hogan EL: Role of calpain and its inhibitors in tissue degeneration and neuroprotection in spinal cord injury. Ann N Y Acad Sci 1997, 825: 120–127. 10.1111/j.1749-6632.1997.tb48421.xCrossRefPubMed

65.

Kampfl A, Posmantur RM, Zhao X, Schmutzhard E, Clifton GL, Hayes RL: Mechanisms of calpain proteolysis following traumatic brain injury: implications for pathology and therapy: implications for pathology and therapy: a review and update. J Neurotrauma 1997, 14: 121–134. 10.1089/neu.1997.14.121CrossRefPubMed

66.

Shields DC, Banik NL: Putative role of calpain in the pathophysiology of experimental optic neuritis. Exp Eye Res 1998, 67: 403–410. 10.1006/exer.1998.0537CrossRefPubMed

67.

Leung L, Cahill CM: TNF-alpha and neuropathic pain–a review. J Neuroinflammation 2010, 7: 27. 10.1186/1742-2094-7-27PubMedCentralCrossRefPubMed

68.

Zheng W, Ouyang H, Zheng X, Liu S, Mata M, Fink DJ, Hao S: Glial TNFalpha in the spinal cord regulates neuropathic pain induced by HIV gp120 application in rats. Mol Pain 2011, 7: 40. 10.1186/1744-8069-7-40PubMedCentralCrossRefPubMed

69.

Niederberger E, Geisslinger G: The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy? FASEB J 2008, 22: 3432–3442. 10.1096/fj.08-109355CrossRefPubMed

70.

Fernyhough P, Smith DR, Schapansky J, Van Der Ploeg R, Gardiner NJ, Tweed CW, Kontos A, Freeman L, Purves-Tyson TD, Glazner GW: Activation of nuclear factor-kappaB via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons. J Neurosci 2005, 25: 1682–1690. 10.1523/JNEUROSCI.3127-04.2005CrossRefPubMed

71.

Pollock G, Pennypacker KR, Memet S, Israel A, Saporta S: Activation of NF-kappaB in the mouse spinal cord following sciatic nerve transection. Exp Brain Res 2005, 165: 470–477. 10.1007/s00221-005-2318-6CrossRefPubMed

72.

Kanngiesser M, Haussler A, Myrczek T, Kusener N, Lim HY, Geisslinger G, Niederberger E, Tegeder I: Inhibitor kappa B kinase beta dependent cytokine upregulation in nociceptive neurons contributes to nociceptive hypersensitivity after sciatic nerve injury. J Pain 2012, 13: 485–497. 10.1016/j.jpain.2012.02.010CrossRefPubMed

73.

Degterev A, Boyce M, Yuan J: A decade of caspases. Oncogene 2003, 22: 8543–8567. 10.1038/sj.onc.1207107CrossRefPubMed

74.

Ferri KF, Kroemer G: Organelle-specific initiation of cell death pathways. Nat Cell Biol 2001, 3: E255-E263. 10.1038/ncb1101-e255CrossRefPubMed

75.

Moore JD, Rothwell NJ, Gibson RM: Involvement of caspases and calpains in cerebrocortical neuronal cell death is stimulus-dependent. Br J Pharmacol 2002, 135: 1069–1077. 10.1038/sj.bjp.0704538PubMedCentralCrossRefPubMed

76.

Sugimoto T, Bennett GJ, Kajander KC: Transsynaptic degeneration in the superficial dorsal horn after sciatic nerve injury: effects of a chronic constriction injury, transection, and strychnine. Pain 1990, 42: 205–213. 10.1016/0304-3959(90)91164-ECrossRefPubMed

77.

Whiteside GT, Munglani R: Cell death in the superficial dorsal horn in a model of neuropathic pain. J Neurosci Res 2001, 64: 168–173. 10.1002/jnr.1062CrossRefPubMed

78.

Scholz J, Broom DC, Youn DH, Mills CD, Kohno T, Suter MR, Moore KA, Decosterd I, Coggeshall RE, Woolf CJ: Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J Neurosci 2005, 25: 7317–7323. 10.1523/JNEUROSCI.1526-05.2005CrossRefPubMed

79.

Joseph EK, Levine JD: Caspase signalling in neuropathic and inflammatory pain in the rat. Eur J Neurosci 2004, 20: 2896–2902. 10.1111/j.1460-9568.2004.03750.xCrossRefPubMed

Title: Transcriptional mechanisms underlying sensitization of peripheral sensory neurons by Granulocyte-/Granulocyte-macrophage colony stimulating factors
Authors: Kiran Kumar Bali
Varun Venkataramani
Venkata P Satagopam
Pooja Gupta
Reinhard Schneider
Rohini Kuner
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Molecular Pain / Issue 1/2013
Electronic ISSN: 1744-8069
DOI: https://doi.org/10.1186/1744-8069-9-48

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Transcriptional mechanisms underlying sensitization of peripheral sensory neurons by Granulocyte-/Granulocyte-macrophage colony stimulating factors

Abstract

Background

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

Peripheral nerve injury is accompanied by chronic transcriptome-wide changes in the mouse prefrontal cortex

Voluntary movements as a possible non-reflexive pain assay

No evidence for the development of acute analgesic tolerance during and hyperalgesia after prolonged remifentanil administration in mice

Shaped magnetic field pulses by multi-coil repetitive transcranial magnetic stimulation (rTMS) differentially modulate anterior cingulate cortex responses and pain in volunteers and fibromyalgia patients

Genome-wide association study of sensory disturbances in the inferior alveolar nerve after bilateral sagittal split ramus osteotomy

Brain-derived neurotrophic factor enhances the excitability of small-diameter trigeminal ganglion neurons projecting to the trigeminal nucleus interpolaris/caudalis transition zone following masseter muscle inflammation